about
Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selectionDevelopments in renal pharmacogenomics and applications in chronic kidney diseaseMolecular evolution and functional divergence of the cytochrome P450 3 (CYP3) Family in Actinopterygii (ray-finned fish)Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients.The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors.Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.PharmGKB summary: cyclosporine and tacrolimus pathwaysThe inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme.Lentiviral transgenic microRNA-based shRNA suppressed mouse cytochromosome P450 3A (CYP3A) expression in a dose-dependent and inheritable manner.CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Clinically relevant genetic variations in drug metabolizing enzymes.Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.Cytochrome P450 3A Enzymes Catalyze the O6-Demethylation of Thebaine, a Key Step in Endogenous Mammalian Morphine BiosynthesisMetabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation.Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5.Pharmacogenetic pathway analysis of docetaxel elimination.Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maravirocClobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studiesAssociation between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemmiRNA-27b levels are associated with CYP3A activity in vitro and in vivo.Cytochrome P450 reaction-phenotyping: an industrial perspective.Cytochromes P450: a structure-based summary of biotransformations using representative substrates.Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations.Pharmacogenetics of analgesics: toward the individualization of prescription.Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?CYP3A5 and ABCB1 genes and hypertension.Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patientsWeight of evidence evaluation of potential human cancer risks from exposure to polychlorinated biphenyls: an update based on studies published since 2003.Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activityThe missing linkage: what pharmacogenetic associations are left to find in CYP3A?Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.Pharmacogenetics and human genetic polymorphisms.Pharmacogenomics of the triazole antifungal agent voriconazole.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Genetic variation in CYP3A43 is associated with response to antipsychotic medication.
P2860
Q24658486-79723FEF-D1E2-425A-84C3-1E52902E1EA5Q26999279-A77CC71B-1BB0-4939-8451-46779718E699Q28744313-5E7AB901-3350-446E-A51D-AF9A451A0EC4Q31133709-0F46678F-E6A8-4630-B29C-0742CAD46D61Q33660484-A2D98B58-7635-4DD9-A23A-9D83429C645CQ33849108-A202246B-A5E6-41D0-928F-8AF08A5CF5EEQ33989902-975BF5CA-054E-4817-93DD-0873465C45F5Q34076521-75C16749-B27A-45BD-85D0-5094DF54ADD9Q34146238-CDA44226-258C-4422-AD33-FBAA208C0798Q34360012-2C075243-63F2-4904-A579-61F90E2094A2Q35032378-89A2C72B-5335-483F-A801-5391E6F13E91Q35818743-C83ABC5C-DF8D-45C9-8EAF-1F771331D87DQ35953101-54E35E19-F8D3-4E99-81D0-7A6169FFE545Q36157386-16418879-3E47-472C-9B54-CEFFA9992379Q36174275-4D7EB750-F786-417D-A054-2081B36C943CQ36182023-9DAC2128-02DE-40F1-B2E4-E1728D35FCEDQ36285918-5CA0FA0D-1502-4BF3-AB4C-CE2C0B02B107Q36406298-84226436-B4D0-4110-8FE7-7B3E5910E0C2Q36537180-31867002-D1F3-43C4-A396-E15688301699Q36603665-931C37D0-34FF-44CD-B0BC-5A9FF9B9C0BBQ36634077-8E7EB4FA-C4EF-45AB-ADA5-FCAC2A80B8C8Q36648836-9E6E43EE-8F32-48FC-BECE-153FAFA72801Q36960539-A26A8F79-E813-4B1C-BD94-F6B56DDECC88Q37079954-156726B1-C075-406A-B820-0C5239799834Q37137128-0946AE1F-44F3-4874-A74D-7DE5CD0B4BB6Q37205954-2AECFCE3-44BD-4BE2-B799-F9D9241D0585Q37271799-498D7A0D-5412-4791-9DBF-9A7BAD0F178BQ37416133-3FC9447D-3C34-4E4D-B0F1-AC213CCD376EQ37439873-96A6A36B-D4A5-4728-B00E-9FE2025B26D0Q37514286-548A042D-5AB9-42FC-A7C5-5C18917A1D85Q37603873-19D21A59-E391-4E28-8EF7-6F811B930E84Q37646778-03C1F672-D2F1-4421-85F1-0AF179DC00E6Q37715233-578D410E-9A2B-4236-A545-3661C5B6085EQ37772183-78502B42-CE90-4F1E-ACA4-6BB98F06F67AQ37892536-4AAAD4A8-BA13-4255-B57F-2869AC3E8984Q37939200-EB6B7CDB-CB82-45B7-B9F1-441D8A292783Q37945308-93798D73-9F9D-4AB3-AB48-E1E530A25BA4Q38068539-A64F39BC-5BD7-4A63-BBBF-B56A5FC22960Q38086777-23ED820B-4546-40AA-ABE2-E012BB1EBFD0Q38242595-E988A58A-2CB2-4CE9-94C8-124A132B97DA
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Significance of the minor cytochrome P450 3A isoforms.
@ast
Significance of the minor cytochrome P450 3A isoforms.
@en
type
label
Significance of the minor cytochrome P450 3A isoforms.
@ast
Significance of the minor cytochrome P450 3A isoforms.
@en
prefLabel
Significance of the minor cytochrome P450 3A isoforms.
@ast
Significance of the minor cytochrome P450 3A isoforms.
@en
P1476
Significance of the minor cytochrome P450 3A isoforms
@en
P2093
Ann K Daly
P356
10.2165/00003088-200645010-00002
P50
P577
2006-01-01T00:00:00Z
P6179
1043445170